{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:37:35Z","timestamp":1787611055106,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79865-3","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T13:41:16Z","timestamp":1731678076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody"],"prefix":"10.1038","volume":"14","author":[{"given":"Hang","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"79865_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng, M. et al. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat. Rev. Cancer 19, 568\u2013586. https:\/\/doi.org\/10.1038\/s41568-019-0183-z (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"79865_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-016-0381-z","volume":"10","author":"X Liu","year":"2017","unstructured":"Liu, X., Kwon, H., Li, Z. & Fu, Y. X. Is CD47 an innate immune checkpoint for tumor evasion?. J. Hematol. Oncol. 10, 12. https:\/\/doi.org\/10.1186\/s13045-016-0381-z (2017).","journal-title":"J. Hematol. Oncol."},{"key":"79865_CR3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 379, 1711\u20131721. https:\/\/doi.org\/10.1056\/NEJMoa1807315 (2018).","journal-title":"N. Engl. J. Med."},{"key":"79865_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","volume":"30","author":"AS Folkes","year":"2018","unstructured":"Folkes, A. S. et al. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience. Curr. Opin. Oncol. 30, 332\u2013337. https:\/\/doi.org\/10.1097\/CCO.0000000000000468 (2018).","journal-title":"Curr. Opin. Oncol."},{"key":"79865_CR5","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim, D. et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26, 2538\u20132545. https:\/\/doi.org\/10.1038\/leu.2012.141 (2012).","journal-title":"Leukemia"},{"key":"79865_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMc1816156","volume":"380","author":"Y Li","year":"2019","unstructured":"Li, Y. CD47 blockade and rituximab in non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 380, 497. https:\/\/doi.org\/10.1056\/NEJMc1816156 (2019).","journal-title":"N. Engl. J. Med."},{"key":"79865_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prp.2018.10.021","volume":"215","author":"K Yang","year":"2019","unstructured":"Yang, K., Xu, J., Liu, Q., Li, J. & Xi, Y. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma\/leukemia. Pathol. Res. Pract. 215, 265\u2013271. https:\/\/doi.org\/10.1016\/j.prp.2018.10.021 (2019).","journal-title":"Pathol. Res. Pract."},{"key":"79865_CR8","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.celrep.2018.07.062","volume":"24","author":"X Liu","year":"2018","unstructured":"Liu, X. et al. Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell Rep. 24, 2101\u20132111. https:\/\/doi.org\/10.1016\/j.celrep.2018.07.062 (2018).","journal-title":"Cell Rep."},{"key":"79865_CR9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209\u20131215. https:\/\/doi.org\/10.1038\/nm.3931 (2015).","journal-title":"Nat. Med."},{"issue":"1324\u20131340","key":"79865_CR10","doi-asserted-by":"publisher","first-page":"e1328","DOI":"10.1016\/j.ccell.2022.10.012","volume":"40","author":"Z Zhou","year":"2022","unstructured":"Zhou, Z. et al. Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. Cancer Cell 40(1324\u20131340), e1328. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.012 (2022).","journal-title":"Cancer Cell"},{"key":"79865_CR11","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U. S. A. 109, 6662\u20136667. https:\/\/doi.org\/10.1073\/pnas.1121623109 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"79865_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080882","author":"Y Si","year":"2021","unstructured":"Si, Y. et al. Anti-CD47 monoclonal antibody-drug conjugate: A targeted therapy to treat triple-negative breast cancers. Vaccines https:\/\/doi.org\/10.3390\/vaccines9080882 (2021).","journal-title":"Vaccines"},{"key":"79865_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic, B. I. et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J. Clin. Oncol. 37, 946\u2013953. https:\/\/doi.org\/10.1200\/JCO.18.02018 (2019).","journal-title":"J. Clin. Oncol."},{"key":"79865_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMc1816156","volume":"380","author":"R Advani","year":"2019","unstructured":"Advani, R., Volkmer, J. P. & Chao, M. P. CD47 blockade and rituximab in non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 380, 497\u2013498. https:\/\/doi.org\/10.1056\/NEJMc1816156 (2019).","journal-title":"N. Engl. J. Med."},{"key":"79865_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699\u2013713. https:\/\/doi.org\/10.1016\/j.cell.2010.07.044 (2010).","journal-title":"Cell"},{"key":"79865_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172 (2015).","journal-title":"Science"},{"key":"79865_CR17","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1038\/s41598-023-32547-y","volume":"13","author":"H Ke","year":"2023","unstructured":"Ke, H. et al. HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models. Sci. Rep. 13, 5419. https:\/\/doi.org\/10.1038\/s41598-023-32547-y (2023).","journal-title":"Sci. Rep."},{"key":"79865_CR18","doi-asserted-by":"publisher","first-page":"175883592110205","DOI":"10.1177\/17588359211020528","volume":"13","author":"R Liu","year":"2021","unstructured":"Liu, R. et al. Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors. Ther. Adv. Med. Oncol. 13, 17588359211020528. https:\/\/doi.org\/10.1177\/17588359211020528 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"79865_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001279","author":"Y Song","year":"2020","unstructured":"Song, Y. et al. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-001279 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"79865_CR20","doi-asserted-by":"publisher","first-page":"1864908","DOI":"10.1080\/2162402X.2020.1864908","volume":"10","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. Oncoimmunology 10, 1864908. https:\/\/doi.org\/10.1080\/2162402X.2020.1864908 (2020).","journal-title":"Oncoimmunology"},{"key":"79865_CR21","doi-asserted-by":"publisher","first-page":"1724751","DOI":"10.1080\/19420862.2020.1724751","volume":"12","author":"J Zhang","year":"2020","unstructured":"Zhang, J., Huang, Y., Xi, G. & Zhang, F. HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. MAbs 12, 1724751. https:\/\/doi.org\/10.1080\/19420862.2020.1724751 (2020).","journal-title":"MAbs"},{"key":"79865_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11882-015-0580-7","volume":"16","author":"S Crescioli","year":"2016","unstructured":"Crescioli, S. et al. IgG4 characteristics and functions in cancer immunity. Curr. Allergy Asthma Rep. 16, 7. https:\/\/doi.org\/10.1007\/s11882-015-0580-7 (2016).","journal-title":"Curr. Allergy Asthma Rep."},{"key":"79865_CR23","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1158\/1535-7163.MCT-17-1095","volume":"17","author":"V Buatois","year":"2018","unstructured":"Buatois, V. et al. Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia. Mol. Cancer Ther. 17, 1739\u20131751. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1095 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"79865_CR24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013901","author":"X Cao","year":"2022","unstructured":"Cao, X. et al. Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced suppression. Blood https:\/\/doi.org\/10.1182\/blood.2021013901 (2022).","journal-title":"Blood"},{"key":"79865_CR25","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","volume":"9","author":"MP Chao","year":"2019","unstructured":"Chao, M. P. et al. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front. Oncol. 9, 1380. https:\/\/doi.org\/10.3389\/fonc.2019.01380 (2019).","journal-title":"Front. Oncol."},{"issue":"163\u2013171","key":"79865_CR26","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/j.exphem.2013.11.005","volume":"42","author":"C Iwamoto","year":"2014","unstructured":"Iwamoto, C. et al. The BALB\/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment. Exp. Hematol. 42(163\u2013171), e161. https:\/\/doi.org\/10.1016\/j.exphem.2013.11.005 (2014).","journal-title":"Exp. Hematol."},{"key":"79865_CR27","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2012-06-440354","volume":"121","author":"T Yamauchi","year":"2013","unstructured":"Yamauchi, T. et al. Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. Blood 121, 1316\u20131325. https:\/\/doi.org\/10.1182\/blood-2012-06-440354 (2013).","journal-title":"Blood"},{"issue":"36\u201344","key":"79865_CR28","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/j.exphem.2016.09.004","volume":"45","author":"X An","year":"2017","unstructured":"An, X. et al. AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and thus, ultimately distinct therapeutic outcomes. Exp. Hematol. 45(36\u201344), e32. https:\/\/doi.org\/10.1016\/j.exphem.2016.09.004 (2017).","journal-title":"Exp. Hematol."},{"key":"79865_CR29","doi-asserted-by":"publisher","first-page":"109637","DOI":"10.1016\/j.clim.2023.109637","volume":"251","author":"Y Lu","year":"2023","unstructured":"Lu, Y. et al. OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma. Clin. Immunol. 251, 109637. https:\/\/doi.org\/10.1016\/j.clim.2023.109637 (2023).","journal-title":"Clin. Immunol."},{"key":"79865_CR30","doi-asserted-by":"crossref","unstructured":"Roohullah A et al. First-in-human phase I dose escalation study of HX009, a novel recombinant humanized anti-CD47\/PD-1 bispecific antibody, in patients with advanced malignancies. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.2517 (2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.2517"},{"key":"79865_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","volume":"11","author":"H Yang","year":"2023","unstructured":"Yang, H., Xun, Y. & You, H. The landscape overview of CD47-based immunotherapy for hematological malignancies. Biomark. Res. 11, 15. https:\/\/doi.org\/10.1186\/s40364-023-00456-x (2023).","journal-title":"Biomark. Res."},{"key":"79865_CR32","doi-asserted-by":"publisher","first-page":"e0187262","DOI":"10.1371\/journal.pone.0187262","volume":"12","author":"GHY Lin","year":"2017","unstructured":"Lin, G. H. Y. et al. TTI-621 (SIRPalphaFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS One 12, e0187262. https:\/\/doi.org\/10.1371\/journal.pone.0187262 (2017).","journal-title":"PLoS One"},{"key":"79865_CR33","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1158\/1078-0432.CCR-15-2503","volume":"22","author":"EC Piccione","year":"2016","unstructured":"Piccione, E. C. et al. SIRPalpha-antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells. Clin. Cancer Res. 22, 5109\u20135119. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2503 (2016).","journal-title":"Clin. Cancer Res."},{"key":"79865_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/19420862.2017.1409319","volume":"10","author":"B Liu","year":"2018","unstructured":"Liu, B. et al. Elimination of tumor by CD47\/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. MAbs 10, 315\u2013324. https:\/\/doi.org\/10.1080\/19420862.2017.1409319 (2018).","journal-title":"MAbs"},{"key":"79865_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg8693","author":"A Zhang","year":"2021","unstructured":"Zhang, A. et al. Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abg8693 (2021).","journal-title":"Sci. Transl. Med."},{"key":"79865_CR36","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1080\/19420862.2015.1062192","volume":"7","author":"EC Piccione","year":"2015","unstructured":"Piccione, E. C. et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 7, 946\u2013956. https:\/\/doi.org\/10.1080\/19420862.2015.1062192 (2015).","journal-title":"MAbs"},{"key":"79865_CR37","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","volume":"10","author":"Y Fu","year":"2020","unstructured":"Fu, Y., Lin, Q., Zhang, Z. & Zhang, L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm. Sin. B 10, 414\u2013433. https:\/\/doi.org\/10.1016\/j.apsb.2019.08.010 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"79865_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0065-2776(10)05003-0","volume":"105","author":"N Ishii","year":"2010","unstructured":"Ishii, N., Takahashi, T., Soroosh, P. & Sugamura, K. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv. Immunol. 105, 63\u201398. https:\/\/doi.org\/10.1016\/S0065-2776(10)05003-0 (2010).","journal-title":"Adv. Immunol."},{"key":"79865_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-1-4939-9145-7_12","volume-title":"Target Identification and Validation in Drug Discovery: Methods and Protocols, Methods in Molecular Biology","author":"DXA Chen","year":"2019","unstructured":"Chen, D. X. A. In vivo pharmacology models for cancer target research. In Target Identification and Validation in Drug Discovery: Methods and Protocols, Methods in Molecular Biology (eds Moll, J. & Carotta, S.) 183\u2013211 (Springer, 2019)."},{"key":"79865_CR40","doi-asserted-by":"publisher","first-page":"E74","DOI":"10.1002\/ijc.27813","volume":"132","author":"M Yang","year":"2013","unstructured":"Yang, M. et al. Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients. Int. J. Cancer 132, E74-84. https:\/\/doi.org\/10.1002\/ijc.27813 (2013).","journal-title":"Int. J. Cancer"},{"key":"79865_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.02.002","volume":"173","author":"QX Li","year":"2017","unstructured":"Li, Q. X., Feuer, G., Ouyang, X. & An, X. Experimental animal modeling for immuno-oncology. Pharmacol. Ther. 173, 34\u201346. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.002 (2017).","journal-title":"Pharmacol. Ther."},{"key":"79865_CR42","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134728","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Targeting macrophage checkpoint inhibitor SIRPalpha for anticancer therapy. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.134728 (2020).","journal-title":"JCI Insight"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79865-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79865-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79865-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T14:04:44Z","timestamp":1731679484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79865-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79865"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79865-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are employees of the affiliated organizations listed. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28201"}}